drugset / Trial / NCT03602131
Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This study is to explore the efficacy and safety of ChiCGB conditioning therapy in patients with high-risk Hodgkin and non-Hodgkin lymphoma.
Timeline
- Start
- 2019-01-01
- Primary completion
- 2020-12-30
- Completion
- 2021-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Busulfan | Small molecule | 3.2 mg/kg | Intravenous |
| Background | Cladribine | Small molecule | 6 mg/m2 | Intravenous |
| Background | Gemcitabine | Small molecule | 2500 mg/m2 | Intravenous |
| Background | Tucidinostat | Small molecule | 30 mg | Oral |